KSD 201
Alternative Names: KSD-201Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Kousai Bio
- Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal cell carcinoma
Most Recent Events
- 30 Nov 2024 Kousai Bio plans a Early phase I trial for Clear Cell Renal Cell Carcinoma (Late-stage disease, Second-line therapy or greater) in China (SC, Injection) (NCT06708936)
- 29 Nov 2024 Preclinical trials in Renal cell carcinoma in South Korea (SC)